Cizzle Brands Strengthens U.S. Footprint of CWENCH Hydration™ With Availability at United Supermarkets in Texas
This press release features multimedia. View the full release here:
The 10-count hydration mix format of CWENCH Hydration™ is sold by United Supermarkets in Texas.
As of April 2025, the original four flavours of CWENCH Hydration™ (Blue Raspberry, Cherry Lime, Rainbow Swirl, and Berry Crush) are being sold in the 10-count hydration mix packet format in-store at United Supermarkets. All four SKUs are also available through United Supermarkets' online ordering portal.
United Supermarkets is part of The United Family, which is a wholly-owned subsidiary of S&P MidCap 400 ® component Albertsons Companies, Inc., one of the largest supermarket chains in the United States. The United Family operates 99 stores under five different banners, serving 1.5 million guests per week in 54 Texas and New Mexico communities.
So far in its Fiscal 2025 year, 20% of the Company's $5.64 million in net sales took place in the United States. As Cizzle Brands seeks to further scale the market share of CWENCH Hydration™ across North America, the Company has undertaken initiatives (such as becoming the Official Hydration Partner of USA Hockey) to fortify its U.S. footprint, alongside the strategic selection of retail partners such as United Supermarkets in key geographic areas.
CWENCH Hydration™ is already carried across the Life Time chain of athletic country clubs in the United States, including at over 30 locations across the state of Texas. This placement with United Supermarkets is therefore expected to complement the brand's existing presence in several Texas regions.
Cizzle Brands' Founder, Chairman, and Chief Executive Officer John Celenza commented, 'Each market is different in terms of the optimal tactics for launching a sports nutrition brand. This is why we're taking a patient, strategic, and selective approach to establishing CWENCH Hydration™ in specific U.S. markets, partnering with established and well-known local chains who have the reach and the capabilities to introduce the product to our target audience. We are proud to have CWENCH Hydration™ carried by United Supermarkets in Texas, and we look forward to building out our distribution pipeline in this dynamic and high-growth region of the United States.'
About Cizzle Brands Corporation
Cizzle Brands Corporation is a sports nutrition company that is elevating the game in health and wellness. Through extensive collaboration and testing with leading athletes and trainers across several elite sports, Cizzle Brands has launched two leading product lines in the sports nutrition category: (i) CWENCH Hydration™, a better-for-you sports drink that is now carried in over 1,800 locations in Canada, the United States, and Europe; and (ii) Spoken Nutrition, a premium brand of athlete-grade nutraceuticals that carry the prestigious NSF Certified for Sport ® qualification. All Cizzle Brands products are designed to help people achieve their best in both competitive sports and in living a healthy, vibrant, active lifestyle.
For more information about Cizzle Brands, please visit: https://www.cizzlebrands.com/
On behalf of the Board of Directors of the Company,
CIZZLE BRANDS CORPORATION
'John Celenza'
John Celenza, Founder, Chairman, and Chief Executive Officer
CAUTIONARY NOTE REGARDING FORWARD-LOOKING INFORMATION
This news release contains 'forward-looking information' which may include, but is not limited to, information with respect to the activities, events or developments that the Company expects or anticipates will or may occur in the future, such as, but not limited to: new products of the Company and potential sales and distribution opportunities. Such forward-looking information is often, but not always, identified by the use of words and phrases such as 'plans', 'expects', 'is expected', 'budget', 'scheduled', 'estimates', 'forecasts', 'intends', 'anticipates', or 'believes' or variations (including negative variations) of such words and phrases, or state that certain actions, events or results 'may', 'could', 'would', 'might' or 'will' be taken, occur or be achieved. Various assumptions or factors are typically applied in drawing conclusions or making the forecasts or projections set out in forward-looking information. Those assumptions and factors are based on information currently available to the Company.
Forward looking information involves known and unknown risks, uncertainties and other risk factors which may cause the actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information. Such risks include risks related to increased competition and current global financial conditions, access and supply risks, reliance on key personnel, operational risks, regulatory risks, financing, capitalization and liquidity risks. Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking information. The Company undertakes no obligation, except as otherwise required by law, to update these forward-looking statements if management's beliefs, estimates or opinions, or other factors change.
1-844-588-2088
SOURCE: Cizzle Brands Corporation
Copyright Business Wire 2025.
PUB: 04/10/2025 07:55 AM/DISC: 04/10/2025 07:55 AM
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
5 hours ago
- Yahoo
Elite Pharmaceuticals, Inc. Reports Financial Results for the First Quarter of Fiscal Year 2026 ended June 30, 2025 and Provides Conference Call Information
Conference Call Scheduled for Friday, August 15 at 11:30 AM EDT Northvale, New Jersey--(Newsfile Corp. - August 14, 2025) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products, announced results for the first quarter of fiscal year 2026 ended June 30, 2025 ("First Quarter"). Consolidated revenues for the three-month period ending June 30, 2025, were $40.2 million, an increase of $21.4 million or approximately 114% as compared to the comparable period of the prior fiscal year. Operating profits were $21.7 million, an increase of $17.8 million or approximately 462%, as compared to the comparable period of the prior fiscal year. The increase in operating profits was primarily attributed to sales of Elite's lisdexamfetamine products, which were launched after the comparable period of the prior fiscal year, as well as overall strong growth in the Elite label product lines as compared to the comparable period in the prior fiscal year. Conference Call Information Elite's management will host a conference call to discuss the First Quarter of Fiscal Year 2026 financial results and provide an update on recent business developments. Stockholder questions should be submitted to the company in advance of the call. Date: August 15, 2025 Time: 11:30 AM EDT Dial-in numbers: 1-800-346-7359 (domestic)1-973-528-0008 (international) Conference number: 98840 Questions: dianne@ Financial questions by 7:00 PM EDT on Thursday, August 14, 2025 Audio Replay: The financial statements can be viewed for Elite's First Quarter of Fiscal Year 2026 on Form 10-Q here. About Elite Pharmaceuticals, Pharmaceuticals, Inc. is a specialty pharmaceutical company that develops and distributes niche generic products. Elite specializes in developing, manufacturing, and distributing oral, controlled-release drug products. Elite owns multiple generic products, which it distributes nationally under the Elite Laboratories, Inc. label. Elite also has products licensed to TAGI Pharma. Elite operates a cGMP and DEA-registered research, development, and manufacturing facility in Northvale, NJ. For more information, visit This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, those related to the effects, if any, on future results, performance or other expectations that may have some correlation to the subject matter of this press release. Readers are cautioned that such forward-looking statements involve, without limitation, risks, uncertainties and other factors not under the control of Elite, which may cause actual results, performance or achievements of Elite to be materially different from the results, performance or other expectations that may be implied by these forward-looking statements. These forward-looking statements may include statements regarding the expected timing of approval, if at all, of products by the FDA, and the actions the FDA may require of Elite in order to obtain such approvals. These forward-looking statements are not guarantees of future action or performance. These risks and other factors are discussed, without limitation, in Elite's filings with the Securities and Exchange Commission, including its reports on forms 10-K, 10-Q, and 8-K. Elite is under no obligation to update or alter its forward-looking statements, whether as a result of new information, future events or otherwise. Contact:For Elite Pharmaceuticals, Will, Investor Relations, 518-398-6222Dianne@ To view the source version of this press release, please visit Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Business Wire
5 hours ago
- Business Wire
Sidus Space Reports Second Quarter 2025 Financial Results and Provides Business Update
CAPE CANAVERAL, Fla.--(BUSINESS WIRE)--Sidus Space (NASDAQ: SIDU), (the 'Company' or 'Sidus'), an innovative space and defense technology company, today announced its financial results for the second quarter ended June 30, 2025, and provided a business update. The Company is scheduled to host a conference call and webcast today, Thursday, August 14, at 5:00 p.m. ET. 'Q2 was about disciplined execution and building durable technology assets. We advanced LizzieSat®‑3 commissioning, fully staffed our 24/7 Mission Operations Center, and expanded our proprietary platform with the Fortis™ VPX Command and Data Handling system and Orlaith™ AI Ecosystem, built to move data and insights seamlessly across space, air, land, and sea,' said Carol Craig, Sidus Chairwoman and CEO. 'We invested ahead of revenue to build core IP and capability. As we enter the second half of the year, we're prioritizing commercialization, aligning spend to milestones, and pursuing capital‑efficient ways to turn our technology into revenue.' Operational Highlights for the Quarter Ending June 30, 2025: Completed commissioning of the ADCS system on LizzieSat®-3 with cutting-edge Autonomous, Machine-Learning-Powered on-board GNC software Fully staffed our in-house Mission Operations Center, enabling 24/7 spacecraft monitoring Received Notice of Allowance for our Modular Satellite Platform—a patent that safeguards the intellectual property behind our adaptable and scalable satellite architecture Deployed Orlaith™ AI system in Asia strengthening global AI and analytics offerings Amended and extended the lunar satellite manufacturing contract with Lonestar Holdings, bringing the total potential value to $120 million Continued building and delivering space and defense hardware for commercial and government customers Subsequent Operational Highlights: Designed LizzieLunar™ to address the Moon's unique operational challenges Successfully executed a capital raise to fund key technology initiatives, including dual-use, multi-domain Fortis™ VPX product line, which supports applications across air, land, sea and space Appointed Tiffany Norwood, Founder and CEO of Tribetan and a globally recognized serial entrepreneur and technology pioneer, to the Board of Directors Financial Highlights for the Second Quarter Ending June 30, 2025: Revenue: $1.3 million, up 36% compared to $928,000 in Q2 2024, reflecting a strategic pivot away from legacy services to new commercial models Cost of Revenue: $2.3 million, up 29% from Q2 2024 due to increased satellite and software depreciation and an increase of material and labor costs Gross Profit (Loss): $(1.0) million, compared to $(841,000) loss in Q2 2024 due to reduced contribution from legacy high-margin services as we transition to higher-value, recurring revenue lines SG&A Expenses: $4.3 million, up from $3.1 million in Q2 2024, driven by headcount growth, launch rescheduling, and operational scaling Adjusted EBITDA: Loss of $3.9 million (non-GAAP), compared to a $3.2 million loss in Q2 2024 Net Loss: $5.6 million, versus $4.1 million in Q2 2024, driven by strategic investment and depreciation Cash Position: $3.6 million as of June 30, 2025, versus $1.4 million a year earlier Conference Call and Webcast Event: Sidus Space Second Quarter Financial Results Conference Call Time: 5:00 p.m. Eastern Time Live Call: + 1-877-269-7751 (U.S. Toll-Free) or +1-201-389-0908 (International) Webcast: For interested individuals unable to join the conference call, a dial-in replay of the call will be available until Thursday, August 28, 2025, at 11:59 P.M. ET and can be accessed by dialing +1-844-512-2921 (U.S. Toll-Free) or +1-412-317-6671 (International) and entering replay pin number: 13755242. An online archive of the webcast will be available for three months following the event at About Sidus Space Sidus Space (NASDAQ: SIDU) is an innovative space and defense technology company offering flexible, cost-effective solutions, including satellite manufacturing and technology integration, AI-driven space-based data solutions, mission planning and management operations, AI/ML products and services, and space and defense hardware manufacturing. With its mission of Space Access Reimagined®, Sidus Space is committed to rapid innovation, adaptable and cost-effective solutions, and the optimization of space system and data collection performance. With demonstrated space heritage, including manufacturing and operating its own satellite and sensor system, LizzieSat®, Sidus Space serves government, defense, intelligence, and commercial companies around the globe. Strategically headquartered on Florida's Space Coast, Sidus Space operates a 35,000-square-foot space manufacturing, assembly, integration, and testing facility and provides easy access to nearby launch facilities. For more information, visit: Forward-Looking Statements Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute 'forward-looking statements' within the meaning of The Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements relating to the expected trading commencement and closing dates. The words 'anticipate,' 'believe,' 'continue,' 'could,' 'estimate,' 'expect,' 'intend,' 'may,' 'plan,' 'potential,' 'predict,' 'project,' 'should,' 'target,' 'will,' 'would' and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties related to market conditions and other factors described more fully in the section entitled 'Risk Factors' in Sidus Space's Annual Report on Form 10-K for the year ended December 31, 2024, and other periodic reports filed with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and Sidus Space, Inc. specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise. Non-GAAP Measures To provide investors with additional information in connection with our results as determined in accordance with GAAP, we use non-GAAP measures of adjusted EBITDA. We use adjusted EBITDA in order to evaluate our operating performance and make strategic decisions regarding future direction of the company since it provides a meaningful comparison to our peers using similar measures. We define adjusted EBITDA as net income (as determined by U.S. GAAP) adjusted for interest expense, depreciation and amortization expense, acquisition deal costs, severance costs, capital market and advisory fees, equity-based compensation and warrant costs. These non-GAAP measures may be different from non-GAAP measures made by other companies since not all companies will use the same measures. Therefore, these non-GAAP measures should not be considered in isolation or as a substitute for relevant U.S. GAAP measures and should be read in conjunction with information presented on a U.S. GAAP basis. The following table reconciles adjusted EBITDA to net loss (the most comparable GAAP measure) for the three months ended June 30, 2025 and 2024: (i) Sidus Space incurred increased interest expense due to short-term note payable due in Q4 2024 and interest expense related to an asset based loan. (ii) Sidus Space incurred increased depreciation expense 2025 and 2024 with launch and deployment of satellite fixed asset and related satellite software, as well as new ERP software capitalization. (iii) Sidus Space incurred increased equity based compensation expense due to incentive programs implemented by the Board in 2025. Expand SIDUS SPACE, INC. CONSOLIDATED BALANCE SHEETS June 30, December 31, 2025 2024 Assets (Unaudited) Current assets Cash $ 3,634,693 $ 15,703,579 Accounts receivable 873,557 827,886 Accounts receivable - related parties 1,037,606 641,376 Inventory 370,067 255,716 Contract asset 993,504 1,347,386 Contract asset - related party 107,013 46,953 Prepaid and other current assets 4,155,398 3,429,656 Total current assets 11,171,838 22,252,552 Property and equipment, net 17,179,137 14,891,976 Operating lease right-of-use assets 835,140 121,545 Intangible asset 398,135 398,135 Other assets 85,173 81,359 Total Assets $ 29,669,423 $ 37,745,567 Liabilities and Stockholders' Equity Current liabilities Accounts payable and other current liabilities $ 5,755,965 $ 3,388,667 Accounts payable and accrued interest - related party 774,600 673,743 Contract liability - 16,192 Contract liability - related party 107,013 46,953 Asset-based loan liability 7,881,629 6,902,636 Notes payable - 3,059,767 Operating lease liability 260,311 121,544 Total current liabilities 14,779,518 14,209,502 Operating lease liability - non-current 575,598 - Total Liabilities 15,355,116 14,209,502 Commitments and contingencies - - Stockholders' Equity Preferred Stock: 5,000,000 shares authorized; $0.0001 par value; no shares issued and outstanding Series A convertible preferred stock: 2,000 shares authorized; 0 shares issued and outstanding - - Common stock: 210,000,000 authorized; $0.0001 par value Class A common stock: 200,000,000 shares authorized; 18,204,483 and 15,956,816 shares issued and outstanding, respectively 1,821 1,597 Class B common stock: 10,000,000 shares authorized; 100,000 shares issued and outstanding 10 10 Additional paid-in capital 86,705,397 83,887,682 Accumulated deficit (72,392,921 ) (60,353,224 ) Total Stockholders' Equity 14,314,307 23,536,065 Total Liabilities and Stockholders' Equity $ 29,669,423 $ 37,745,567 Expand SIDUS SPACE, INC. CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) Three Months Ended Six Months Ended June 30, June 30, 2025 2024 2025 2024 Revenue $ 691,070 $ 834,798 $ 851,774 $ 1,679,909 Revenue - related parties 569,953 92,772 647,743 297,816 Total - revenue 1,261,023 927,570 1,499,517 1,977,725 Cost of revenue 2,288,165 1,768,671 4,155,137 2,734,762 Gross profit (loss) (1,027,142 ) (841,101 ) (2,655,620 ) (757,037 ) Operating expenses Selling, general and administrative expense 4,263,269 3,056,814 8,707,711 6,702,397 Total operating expenses 4,263,269 3,056,814 8,707,711 6,702,397 Net loss from operations (5,290,411 ) (3,897,915 ) (11,363,331 ) (7,459,434 ) Other income (expense) Other income - 1,613 - 1,613 Interest expense (2,546 ) (186,175 ) 22,047 (339,701 ) Interest income 27,979 12,313 94,324 12,313 Asset-based loan expense (360,092 ) (65,920 ) (792,737 ) (161,375 ) Total other income (expense) (334,659 ) (238,169 ) (676,366 ) (487,150 ) Loss before income taxes (5,625,070 ) (4,136,084 ) (12,039,697 ) (7,946,584 ) Provision for income taxes - - - - Net loss (5,625,070 ) (4,136,084 ) (12,039,697 ) (7,946,584 ) Dividend on Series A preferred Stock - - - (42,375 ) Net loss attributed to stockholders $ (5,625,070 ) $ (4,136,084 ) $ (12,039,697 ) $ (7,988,959 ) Basic and diluted loss per common share $ (0.31 ) $ (0.99 ) $ (0.66 ) $ (2.32 ) Basic and diluted weighted average number of common shares outstanding 18,320,025 4,181,344 18,274,485 3,450,577 Expand Six Months Ended June 30, 2025 2024 Cash Flows From Operating Activities: Net loss $ (12,039,697 ) $ (7,946,584 ) Adjustments to reconcile net loss to net cash used in operating activities: Stock based compensation 436,692 160,028 Depreciation and amortization 2,066,969 858,033 Non-cash fees on asset-based loan - Bad debt - - Changes in operating assets and liabilities: Accounts receivable (45,671 ) 553,764 Accounts receivable - related party (396,230 ) (197,355 ) Inventory (114,351 ) (182,757 ) Contract asset 353,882 - Contract asset - related party (60,060 ) (2,827 ) Prepaid expenses and other assets (729,556 ) 946,246 Accounts payable and accrued liabilities 2,537,168 (1,968,107 ) Accounts payable and accrued liabilities - related party 100,857 210,363 Contract liability (16,192 ) - Contract liability - related party 60,060 2,827 Changes in operating lease assets and liabilities 770 (3,699 ) Net Cash provided by (used in) Operating Activities (7,845,359 ) (7,570,068 ) Cash Flows From Investing Activities: Purchase of property and equipment (4,354,130 ) (4,067,741 ) Cash paid for asset acquisition - - Net Cash used in Investing Activities (4,354,130 ) (4,067,741 ) Cash Flows From Financing Activities: Proceeds from issuance of common stock units - 13,742,311 Proceeds from exercise of warrants 2,381,247 - Proceeds from asset-based loan agreement 4,413,239 46,133 Repayment of asset-based loan agreement (3,604,116 ) (1,772,373 ) Repayment of notes payable (3,059,767 ) (150,000 ) Net Cash provided by (used in) Financing Activities 130,603 11,866,071 Net change in cash (12,068,886 ) 228,262 Cash, beginning of period 15,703,579 1,216,107 Cash, end of period $ 3,634,693 $ 1,444,369 Supplemental cash flow information Cash paid for interest $ 630,874 $ 338,116 Cash paid for taxes $ - $ - Non-cash Investing and Financing transactions: Conversion interest and fees of asset based loan $ 169,870 $ - Class A common stock issued for conversion of Series A convertible preferred stock $ - $ 16,566 Recognition of right-of-use asset and lease liability $ 856,787 $ 284,861 Expand
Business Wire
6 hours ago
- Business Wire
Tivic Reports Second Quarter 2025 Financial Results
FREMONT, Calif.--(BUSINESS WIRE)-- Tivic Health® Systems, Inc. (NASDAQ: TIVC), a diversified immunotherapeutics company, today announced financial results for the second quarter and six months ended June 30, 2025. 'We have established a strong foundation for Tivic's strategic transformation with our expansion into biopharmaceuticals, making us unique in treating disease by addressing both the body's biochemical and bioelectronic systems,' stated Tivic CEO Jennifer Ernst. 'To maximize our focus on the compelling, late-stage clinical pipeline, we have increasingly shifted resources away from consumer healthtech and are now planning to exit the ClearUP business by the end of this year,' continued Ernst. 'I look forward to advancing the commercialization of these life-saving therapies, supporting our strategy to increase shareholder value through this transformation.' Corporate Highlights from the Second Quarter and Subsequent Weeks, included: Securing positive interest in potential military and defense applications for drug candidate Entolimod™ to treat ARS during briefings with the White House and U.S. Food & Drug Administration (FDA) officials. Extending the worldwide license of Entolimod™ to include the treatment of neutropenia, a condition that reduces the body's ability to combat infections and has a wide range of causes - from genetics to cancer treatments and age. Entering into a GMP manufacturing validation agreement with Scorpius Biomanufacturing, Inc. as part of preparing for the FDA biologics license application process. Completing all study visits in the Optimization Study for its patent-pending, non-invasive cervical vagus nerve stimulation (ncVNS) device. Raising $1.4 million from the first and second tranche of a preferred equity purchase agreement that provides for up to $8.4 million in total financing. Entering into a $25 million equity line of credit that generated net proceeds of $547,000. Receiving shareholder approval of key measures in support of Tivic transformation strategy. Expanding biopharmaceutical team with regulatory, clinical and business development staff. Naming Lisa Wolf as CFO following her nine-month tenure as interim CFO. Financial Performance: Revenue (net of returns) for the three and six months ended June 30, 2025 totaled $86,000 and $156,000, respectively, compared with $140,000 and $474,000 for 2024. The decreases are due to lower unit sales of ClearUP™ to treat sinus pain and pressure. The lower sales are attributable to decreases in advertising expenses as the company focused resources on accelerating its TLR5 program for the development of Entolimod™ for ARS. Gross profit in the three and six months ended June 30, 2025 was $54,000 and $104,000, respectively, compared to $30,000 and $197,000 in 2024. Gross margin was 67% in the six months ended June 30, 2025, compared to 42% in 2024. Operating expenses in the three and six months ended June 30, 2025 was $2.0 million and $3.5 million, respectively, compared to $1.3 million and $3.0 million in 2024. The increases were primarily due to the addition of the biopharma programs in February 2025. Net loss of $1.9 million for the three months ended June 30, 2025, compared to $1.3 million in the second quarter of 2024. Net loss of $3.4 million for the first half of 2025, compared to $2.7 million for the first half of 2024. At June 30, 2025, cash and cash equivalents totaled $1.2 million, compared with $2.0 million, at December 31, 2024. Subsequent to quarter's end, the Company raised a total of $0.9 million through utilization of its equity line of credit and the sale of Series B Preferred Stock pursuant to its preferred equity purchase agreement. The company has no debt on its balance sheet. Approximately $7.0 million remains available as a committed investment in Tivic through a preferred equity purchase agreement. The company believes the current and committed funding is sufficient to make meaningful progress toward manufacturing validation for Entolimod. Conference Call and Webcast Information Management will host a webcast/conference call today, Thursday, August 14, at 1:30 p.m. PT / 4:30 p.m. ET to discuss the company's second quarter 2025 financial results and provide a business update. Webcast Link An audio replay of the call will be available for the next 90 days from the investor page on the Tivic Health website at About Tivic Tivic's dual platform utilizes the body's biopharmaceutical and bioelectronic systems to treat unmet medical needs through targeting the immune system. Tivic's biologics compounds activate an innate immune pathway to prevent cell death in the bone marrow and epithelial tissues across systems impacted by radiation and age. The company's lead drug candidate, Entolimod™ for acute radiation syndrome, is a novel TLR5 agonist that has been granted Fast Track designation and is in late stage development. Tivic's bioelectronic program is developing a novel, non-invasive medical device designed to target the neural pathways implicated in many prevalent and debilitating diseases. Early trials show promising signals that Tivic's approach may regulate specific biologic responses, and the company believes its early-stage vagus nerve stimulation device has the potential to deliver clinical outcomes similar to or better than those of surgically implanted devices. To learn more about Tivic, visit: Forward-Looking Statements This press release may contain 'forward-looking statements' that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as 'anticipate,' 'believe,' 'contemplate,' 'could,' 'estimate,' 'expect,' 'intend,' 'seek,' 'may,' 'might,' 'plan,' 'potential,' 'predict,' 'project,' 'target,' 'aim,' 'should,' 'will,' 'would,' or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Tivic Health Systems, Inc.'s current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate, including as a result of interactions with and guidance from the FDA and other regulatory authorities; changes to the company's relationship with the its partners; the failure to obtain FDA or similar clearances or approvals and noncompliance with FDA or similar regulations; the company's future development of its ncVNS treatment, Entolimod and Entolasta; changes to the company's business strategy; timing and success of clinical trials and study results; regulatory requirements and pathways for approval; consummation of any strategic transactions; the company's need for, and ability to secure when needed, additional working capital; the company's ability to maintain its Nasdaq listing; and changes in tariffs, inflation, legal, regulatory, political and economic risks. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors. Accordingly, you are cautioned not to place undue reliance on such forward-looking statements. For a discussion of risks and uncertainties relevant to the company, and other important factors, see Tivic Health's filings with the SEC, including, its Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on March 21, 2025, under the heading 'Risk Factors," as well as the company's subsequent filings with the SEC. Forward-looking statements contained in this press release are made as of this date, and Tivic Health Systems, Inc. undertakes no duty to update such information except as required by applicable law. Tivic Health Systems, Inc. Condensed Statements of Operations (in thousands, except share and per share data) Three Months Ended June 30, Six Months Ended June 30, 2025 2024 2025 2024 REVENUES $ 86 $ 140 $ 156 $ 474 COST OF SALES 32 110 52 277 GROSS PROFIT 54 30 104 197 OPERATING EXPENSES Research and development 655 302 990 558 Sales and marketing 426 207 605 712 General and administrative 907 787 1,949 1,674 TOTAL OPERATING EXPENSES 1,988 1,296 3,544 2,944 NET OPERATING LOSS (1,934 ) (1,266 ) (3,440 ) (2,747 ) OTHER INCOME, NET 3 0 7 0 NET LOSS $ (1,931 ) $ (1,266 ) $ (3,433 ) $ (2,747 ) NET LOSS PER SHARE - BASIC AND DILUTED $ (2.19 ) $ (5.37 ) $ (4.64 ) $ (17.05 ) WEIGHTED-AVERAGE NUMBER OF SHARES - BASIC AND DILUTED 881,294 235,868 739,618 161,103 Expand
